IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE:AGN) today announced that the company has received approval from the U.S. Food and Drug Administration (FDA) to market JUVÉDERM VOLUMA™ XC, the ...

The FDA has approved Juvéderm Voluma XC as a filler to temporarily correct age-related loss in the cheeks of patients aged 21 years and older, Allergan has announced. The FDA’s approval was based on ...

Dermatologists and plastic surgeons have a new, nonsurgical weapon to add to their anti-aging arsenal. Juvéderm Voluma XC was approved by the U.S. Food and Drug Administration in December as the first ...

Patients interested in learning more about JUVÉDERM ® VOLUMA ® XC for temple hollowing are encouraged to enroll in Allē, the Allergan Aesthetics loyalty rewards program. In serving more than seven ...

Please provide your email address to receive an email when new articles are posted on . “Because there are no permanent adverse reactions or deforming reactions, I ...

IRVINE, Calif.--(BUSINESS WIRE)--Allergan, Inc., (NYSE: AGN) is pleased that the U.S. Food and Drug Administration (FDA) General and Plastic Surgery Devices Panel of the Medical Devices Advisory ...

The US Food and Drug Administration (FDA) has approved Juvéderm Voluma XC (Allergan) to correct age-related volume deficits in the midface in adults aged 21 years and older, the company announced ...

TAMPA, FL--(Marketwired - Jan 23, 2014) - Modern advances in cosmetic surgery can help people achieve life-changing results. But all too often patients chase facial rejuvenation without consideration ...

GROSSE POINTE, Mich., Oct. 25, 2013 /PRNewswire/ -- Board certified cosmetic Dermatologist, Dr. David Balle, of Grosse Pointe Dermatology Associates, P.C.,has been chosen by Allergan, maker of the ...